BCR-ABL tyrosine kinase inhibitors
What are BCR-ABL tyrosine kinase inhibitors
BCR-ABL tyrosine kinase inhibitors inhibit the enzyme BCR-ABL tyrosine kinase, which is important in the pathogenesis of chronic myelogenous leukemia (CML).
Chronic myelogenous leukemia occurs due a single genetic abnormality, known as the Philadelphia chromosome. During the translocation when the Philadelphia chromosome is created, a fusion gene called BCR-ABL gene is formed. The BCR-ABL gene encodes for the BCR-ABL tyrosine kinase. The BCR-ABL positive cells in chronic myelogenous leukemia have increased proliferation and resistance to cell death.
BCR-ABL tyrosine kinase inhibitors are used to treat chronic myelogenous leukemia.
List of BCR-ABL tyrosine kinase inhibitors:
Filter by:
Drug Name  ( View by: Brand | Generic )
|
Reviews | Ratings |
|
|---|---|---|---|
| Bosulif (Pro, More...) generic name: bosutinib |
1 review | 10 | |
| Sprycel (Pro, More...) generic name: dasatinib |
12 reviews | 9.1 | |
| Gleevec (Pro, More...) generic name: imatinib |
30 reviews | 9.0 | |
| Tasigna (Pro, More...) generic name: nilotinib |
19 reviews | 7.8 | |
| Iclusig (Pro, More...) generic name: ponatinib |
2 reviews | 3.0 | |
See also...
Medical conditions associated with BCR-ABL tyrosine kinase inhibitors:
